PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 61 filers reported holding PRELUDE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $496,415 | +37.3% | 160,652 | +100.0% | 0.00% | – |
| Q2 2023 | $361,467 | +123.0% | 80,326 | +182.4% | 0.00% | – |
| Q1 2023 | $162,108 | -5.6% | 28,440 | 0.0% | 0.00% | – |
| Q4 2022 | $171,778 | -7.1% | 28,440 | 0.0% | 0.00% | – |
| Q3 2022 | $185,000 | +25.0% | 28,440 | 0.0% | 0.00% | – |
| Q2 2022 | $148,000 | -24.5% | 28,440 | 0.0% | 0.00% | – |
| Q1 2022 | $196,000 | -44.6% | 28,440 | 0.0% | 0.00% | – |
| Q4 2021 | $354,000 | -60.2% | 28,440 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $889,000 | -2.4% | 28,440 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $911,000 | -26.1% | 28,440 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $1,232,000 | -23.5% | 28,440 | +26.3% | 0.00% | -50.0% |
| Q4 2020 | $1,611,000 | +137.6% | 22,509 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $678,000 | – | 22,509 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $52,407,000 | 0.95% |
| Baker Brothers Advisors | 10,123,824 | $52,846,000 | 0.30% |
| Corton Capital Inc. | 15,586 | $81,000 | 0.08% |
| HHLR ADVISORS, LTD. | 583,333 | $3,045,000 | 0.06% |
| Delphia (USA) Inc. | 16,940 | $88,000 | 0.06% |
| Rock Springs Capital Management LP | 368,959 | $1,926,000 | 0.06% |
| Virtus ETF Advisers LLC | 24,005 | $125,000 | 0.05% |
| CAXTON ASSOCIATES LP | 83,867 | $438,000 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 36,626 | $191,000 | 0.03% |
| PDT Partners, LLC | 43,731 | $228,000 | 0.02% |